The serum levels of TNF-α, CRP and IL-6 in the combined group were lower than those in the GP group after treatment, indicating that WMN can, to a certain extent, restore the immunosuppression produced by the GP regimen, inhibit the undesirable progression of the inflammatory microenvironment, reduce complications, lower postoperative recurrence, and effectively improve the clinical effect of GP treatment for lung cancer patients, which has positive clinical significance (167, 168). The gene discussed is TNF; the disease is lung cancer.